NORML

MARCH 19, 2019

She generated international headlines when she opened the World Famous Cannabis Cafe in 2009, the nation’s first public-facing cannabis consumption lounge. “This is about equal rights because whenever you pick a certain group and treat them differently that is discrimination.

Legalization 189

Legalization Consumption Patients Policy 189

SpeedWeed

MARCH 19, 2021

Also, in 2009, New Zealand became the first country to accept ibogaine as a medication. It granted some healthcare professionals the legal right to use psilocybin to treat some conditions, such as PSTD, depression, and other related cases. In the United States, psychedelics are illegal in most states.

Environment 52

Environment Decriminalization Research and Development Advocacy 52

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access.

Research and Development 52

Research and Development Medicine Access Media 52

SMPL

MAY 26, 2020

In the absence of oversight, the push to get more patients access to cannabis medicine — and bona fide CBD — has been co-opted by a push to make as much money as possible off the next big wellness fad. “At Gardner, the writer whose CBD advocacy eventually inspired the 2011 summit at Ms. We were in communication for many years.”.

CBD 40

CBD Research and Development Pharmaceutical Seed-To-Sale 40

The Cannigma

DECEMBER 12, 2022

And while most psychedelics are currently illegal in the United States and around the world, researchers are exploring their use in medicine to treat conditions such as depression, PTSD, addiction, anxiety, OCD, migraines, end of life acceptance of mortality, and eating disorders. It became illegal in the US in 2009.

History 119

History Microdosing Research and Development Clinical Trials 119

Cannabis Law Report

JUNE 4, 2021

Originally a lawyer, Yang began working in startups and early stage growth companies as a founder or executive from 2000 to 2009. David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. Healing Advocacy Fund.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

JULY 25, 2022

Dr Emma Tumilty, a bioethicist from Deakin University, says that advertisement raised suspicions “that the research was in part being used as a vehicle to provide access to the drug so that MMA could offer training that included that experience”. That would, of course, be ethically and scientifically inappropriate.”

Medicine 52

Medicine Therapy Research and Development Business 52